SYS-CON MEDIA Authors: Jason Bloomberg, Eric Brown, Bob Gourley, Sandi Mappic, RealWire News Distribution

News Feed Item

Free Research Reports on MRK, OMCL, TLAB and ZTS Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY -- (Marketwire) -- 02/04/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Merck & Co., Inc. (NYSE: MRK) shares of the major drug manufacturer declined 3.28 percent on nearly 38 million shares traded Friday, which was more than twice the average daily volume. The company reported a 7 percent drop in net income for the fourth quarter due largely to the patent expiration of Singulair.

Find out more about Merck & Co. including full access to the free equity report at: www.BedfordReport.com/MRK

Omnicell, Inc. (NASDAQ: OMCL) shares posted a gain of 12.7 percent on more than four-times the average daily volume Friday. The company reported revenues in the fourth quarter grew to $90.2 million, an increase of 43.3 percent year-over-year, and 6.9 percent sequentially.

Find out more about Omnicell including full access to the free equity report at: www.BedfordReport.com/OMCL

Tellabs, Inc. (NASDAQ: TLAB) shares dropped 7.7 percent on over 12 million shares traded Friday. The communications company reported their net loss widened to $23 million in the fourth quarter compared to a net loss of $5 million in the fourth quarter of 2011.

Find out more about Tellabs including full access to the free equity report at: www.BedfordReport.com/TLAB

Zoetis Inc. (NYSE: ZTS) formerly Pfizer Inc.'s animal-medicine unit, surged nearly 20 percent on 66.8 million shares traded on its public-trading debut Friday. The Company's more than 300 product lines include vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceutical products.

Find out more about Zoetis including full access to the free equity report at: www.BedfordReport.com/ZTS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.